Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Judy Smith

Nurse Practitioner, Family Tampa, FL Nurse Practitioner

NPI 1225114127 CMS profile 10875990

3450 E Fletcher Ave Ste 350, Tampa, FL 33613

Open in the dashboard

General payments

$9,039

487 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Judy Smith of Tampa, FL is reported in the CMS Open Payments database as having received $9,039 across 487 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,422 74
2024 General $1,464 65
2023 General $1,503 82
2022 General $2,125 112
2021 General $2,524 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Judy Smith
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Judy Smith were reported at $1,422. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Judy Smith Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,524 $124 $35–$379 $132
2022 $2,125 $141 $44–$430 $149
2023 $1,503 $154 $49–$476 $160
2024 $1,464 $165 $51–$504 $164
2025 $1,422 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,566 108 payments
  2. Collegium Pharmaceutical, Inc. $1,269 71 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $691 42 payments
  4. Scilex Pharmaceuticals Inc. $639 30 payments
  5. Pfizer Inc. $572 24 payments
  6. OptiNose US, Inc. $513 6 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $438 24 payments
  8. Amgen Inc. $335 17 payments
  9. Idorsia Pharmaceuticals US Inc $306 18 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $260 12 payments
  11. Other $2,450 135 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,971 486 payments
  2. Education $68 1 payment
Products named General payments · program years 2021–2025
  1. XTAMPZA $1,269 71 payments
  2. UBRELVY $961 62 payments
  3. RELISTOR Gastroenterology $691 42 payments
  4. RELISTOR Gastroenterology $677 41 payments
  5. QULIPTA $662 54 payments
  6. ZTLido $569 27 payments
  7. ZAVZPRET $556 23 payments
  8. Xhance $513 6 payments
  9. NURTEC ODT Pain $479 20 payments
  10. NURTEC ODT Primary Care $390 20 payments
  11. Other $4,123 230 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

3,775

Median for Nurse Practitioner: 389

Drug cost

$283,404

Median for Nurse Practitioner: $21,885

Branded share of claims

12.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 17 $51,247
Nurtec Odt Rimegepant Sulfate Brand 25 $47,450
Movantik Naloxegol Oxalate Brand 64 $26,233
Botox Onabotulinumtoxina Brand 20 $26,130
Belsomra Suvorexant Brand 54 $25,458
Ubrelvy Ubrogepant Brand 12 $17,629
Lidocaine Generic 64 $10,836
Pregabalin Generic 279 $9,125
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 48 $6,916
Diclofenac Sodium Generic 143 $6,624

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$55,538

Of which drugs: $388

Medicare patients

148

Average age 66

Services billed

1,039

90 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 43%
Depression 43%
Ischemic heart disease 37%
COPD 35%
Chronic kidney disease 32%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $345
$345 — —
UBRELVY
  • AbbVie, Inc. $203
$203 12 —
ZTLido
  • Scilex Pharmaceuticals Inc. $159
$159 — —
Xhance
  • OptiNose US, Inc. $136
$136 — —
NURTEC ODT
  • PFIZER INC. $128
$128 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

487 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record